The minutes of the vaccine expert group meeting is out and it shows that the approval of Bharat Biotech's Covaxin was based on non-human primate challenge study.
The minutes of the Subject Expert Committee (SEC) revealed now that the approval under clinical trial mode that has been given based on non-human primate challenge study, which was submitted after multiple times when the Bharat Biotech application was rejected and sent back by the SEC.
On December, 13th SEC has told Bharat Biotech that they need to submit updated immunogenicity, safety, and efficacy dated for further consideration.
CNBC-TV18’s Archana Shukla gets more details.
To know more, watch this video.